ImCheck Therapeutics Revenue

Biotechnology Research • Marseille, Provence-Alpes-Côte d'Azur, France • 51-100 Employees

ImCheck Therapeutics revenue & valuation

Annual revenue	$4,500,000
Revenue per employee	$81,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$14,400,000
Total funding	$122,400,000

Key Contacts at ImCheck Therapeutics

Noemi Angelosanto

Senior Medical Director

Pierre D'Epenoux

Chief Executive Officer

Anne Viseur

Interim Human Resources Director

Katrien Lemmens

Senior Medical Director At Imcheck Therapeutics

Cristina Ghirelli

Researh Operations Director

Diane Delpy-Sampson

Associate Director, Program Management

Jessica Renaux

Director Of Clinical Operations

Charlotte Reynaud Desreux

Senior Director, Qa & Compliance

Carla Cano

Lead Discovery Director

Alem Truneh

Co-Founder & Advisor At Imcheck Therapeutics

Company overview

Headquarters	31 chemin Joseph Aiguier CS 70071, Marseille, Provence-Alpes-Cote d'Azur 13009, FR
Phone number	+33413961490
Website	imchecktherapeutics.com
SIC	873
Keywords	Oncology, Immuno-Oncology, Cancer, Antibodies, Auto-Immunity, Evictiontrial, Immune Checkpoint Modulators, Adaptative Immunity, Innate Immunity, Precision-Based Medicine, Ict01, Gamma-Deltatcells
Founded	2015
Employees	51-100
Socials

ImCheck Therapeutics Email Formats

ImCheck Therapeutics uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@imchecktherapeutics.com), used 100% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@imchecktherapeutics.com	100%

About ImCheck Therapeutics

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Director

Manager

Employees by Department

ImCheck Therapeutics has 34 employees across 10 departments.

Departments

Number of employees

Funding Data

Explore ImCheck Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2022-07-13	6	$100,000,000
2024-09-29	9	$22,400,000

Funding Insights

$122,400,000

Total funding amount

$22,400,000

Most recent funding amount

Number of funding rounds

ImCheck Therapeutics Tech Stack

Discover the technologies and tools that power ImCheck Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Cloudflare

CDN

Modernizr

JavaScript libraries

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

Google Tag Manager

Tag managers

PHP

Programming languages

Open Graph

Miscellaneous

Font Awesome

Font scripts

OVHcloud

Hosting

TYPO3 CMS

CMS

PWA

Miscellaneous

Google Analytics

Analytics

Frequently asked questions

ImCheck Therapeutics is located in Marseille, Provence-Alpes-Côte d'Azur, FR.

You can reach ImCheck Therapeutics at +33413961490.

ImCheck Therapeutics generates an estimated annual revenue of $4,500,000. This revenue figure reflects the company's market position and business performance in its industry.

ImCheck Therapeutics has an estimated valuation of $14,400,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

ImCheck Therapeutics was founded in 2015, making it 11 years old. The company has established itself as a significant player in its industry over this time.

ImCheck Therapeutics has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

ImCheck Therapeutics has raised a total of $122,400,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.